Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study

The Journal of Allergy and Clinical Immunology
Kenji KabashimaThomas Ruzicka

Abstract

Nemolizumab, an anti-IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933). We sought to assess the long-term efficacy and safety of nemolizumab injected subcutaneously every 4 weeks (Q4W) or every 8 weeks (Q8W) in a 52-week, double-blind extension (part B). During part B, patients continued the previous nemolizumab dose (0.1, 0.5, or 2.0 mg/kg Q4W or 2.0 mg/kg Q8W). Part B end points included percentage improvement from baseline in pruritus visual analog scale and dermatitis scores (including the Eczema Area and Severity Index). Overall, 216 of 264 patients completed part A, and 191 entered part B; 131 completed part B. In 153 patients randomized to nemolizumab in part A, improvement from baseline in pruritus visual analog scale score was maintained/increased from weeks 12 to 64, with greatest improvement in the 0.5-mg/kg Q4W group (percentage change from baseline at week 64: -73.0, -89.6, -74.7, and -79.1 in the 0.1-, 0.5-, and 2.0-mg/kg Q4W and 2.0-mg/kg Q8W groups, respectively). Improvement from baseline in dermat...Continue Reading

Associated Clinical Trials

References

Jun 9, 2004·Nature Immunology·Stacey R DillonJane A Gross
Mar 14, 2007·The Journal of Experimental Medicine·Jacqueline G PerrigoueDavid Artis
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jacqueline G PerrigoueDavid Artis
Oct 20, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Janine BilsboroughStacey R Dillon
May 25, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·D Chrostowska-PlakJ C Szepietowski
Jul 21, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·J RingUNKNOWN Global Allergy and Asthma European Network
Apr 9, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·A LangenbruchM Augustin
Jan 1, 2014·The Journal of Allergy and Clinical Immunology·Ferda CevikbasMartin Steinhoff
Mar 29, 2014·Journal of Dermatological Science·Atsuhiko KatoAkimichi Morita
May 13, 2014·Journal of the American Academy of Dermatology·Robert SidburyUNKNOWN American Academy of Dermatology
May 13, 2014·Journal of the American Academy of Dermatology·Lawrence F EichenfieldRobert Sidbury
Sep 18, 2014·Acta Dermato-venereologica·Makiko Kido-NakaharaMasutaka Furue
Jan 24, 2015·Dermatology : International Journal for Clinical and Investigative Dermatology·M K A BasraA Y Finlay
Mar 6, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kai H HänelJens M Baron
Mar 24, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·A WollenbergUNKNOWN European Task Force on Atopic Dermatitis/EADV Eczema Task Force
May 24, 2016·The Journal of Allergy and Clinical Immunology·Micha FeldBernhard Homey
Jun 1, 2016·Current Medical Research and Opinion·Jennifer WhiteleyGeoffrey Makinson
Aug 9, 2016·The Journal of Allergy and Clinical Immunology·Thomas WerfelCezmi A Akdis
Aug 9, 2016·The Journal of Allergy and Clinical Immunology·Gyohei Egawa, Kenji Kabashima
Sep 28, 2016·The Journal of Allergy and Clinical Immunology·Hitokazu EsakiEmma Guttman-Yassky
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Dec 10, 2016·The Journal of Allergy and Clinical Immunology·Takashi Nomura, Kenji Kabashima
Mar 2, 2017·The New England Journal of Medicine·Thomas RuzickaUNKNOWN XCIMA Study Group
Apr 22, 2017·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Saburo SaitoHiroshi Kiyonari

❮ Previous
Next ❯

Citations

Nov 15, 2018·Expert Opinion on Investigational Drugs·Manuel P Pereira, Sonja Ständer
Dec 19, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·U Blume-PeytaviT Nocera
Jan 24, 2019·Expert Opinion on Biological Therapy·Randall LiEmma Guttman-Yassky
Mar 1, 2019·Current Allergy and Asthma Reports·Mario Sánchez-BorgesIgnacio Ansotegui Zubeldia
Jul 6, 2019·European Journal of Immunology·Julia Matthias, Christina E Zielinski
Jul 19, 2019·Immunological Medicine·Hiraku Suga, Shinichi Sato
Aug 1, 2019·Paediatric Drugs·Henry L NguyenMegha M Tollefson
Jul 30, 2019·European Journal of Immunology·Lorenzo CosmiFrancesco Annunziato
Jul 17, 2019·Experimental Dermatology·Martin Metz
Sep 13, 2019·Dermatology and Therapy·Claudia ZeidlerSonja Ständer
Oct 1, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·G YosipovitchM S Fassett
Oct 17, 2019·Archives of Dermatological Research·Tomasz HawroMarcus Maurer
Jan 30, 2020·Expert Review of Clinical Immunology·Kim Jackson, Sami L Bahna
Aug 25, 2019·Allergy·Stefanie EyerichKilian Eyerich
Dec 24, 2019·Physiological Reviews·Ferda Cevikbas, Ethan A Lerner
Jun 9, 2020·The Journal of Dermatological Treatment·Shelley K UppalJashin J Wu
Jul 9, 2020·The New England Journal of Medicine·Kenji KabashimaUNKNOWN Nemolizumab-JP01 Study Group
Jul 28, 2020·Expert Opinion on Emerging Drugs·Kayla FourzaliGil Yosipovitch
Mar 5, 2019·The Journal of Dermatological Treatment·Yiqiu YaoSimon Francis Thomsen
Jul 25, 2020·Expert Opinion on Investigational Drugs·Laura CalabreseKetty Peris
Aug 8, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Michael P SchönKerstin Steinbrink
May 28, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Thomas Litman
Nov 27, 2019·International Journal of Molecular Sciences·Giuseppe MurdacaSebastiano Gangemi
Jul 2, 2020·Clinical Reviews in Allergy & Immunology·Chia-Yu Chu
Sep 4, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Michael P SchönKerstin Steinbrink
Jul 2, 2020·American Journal of Clinical Dermatology·Radomir ReszkeJacek C Szepietowski
Jul 29, 2020·Expert Review of Clinical Immunology·Sonja SennerAndreas Wollenberg
Mar 19, 2019·The Journal of Clinical Investigation·Willem van de Veen, Mübeccel Akdis
Jun 11, 2020·Drugs·Megan NewsomLindsay C Strowd
Jul 10, 2019·Frontiers in Immunology·Bernhard F GibbsUlrike Raap
Oct 31, 2018·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Vincent HoffmannSonja Ständer
Jul 10, 2019·International Journal of Molecular Sciences·Dugarmaa UlziiMasutaka Furue
Jul 12, 2019·Frontiers in Immunology·Claudia ZeidlerSonja Ständer
Dec 19, 2019·Frontiers in Immunology·Farzan SolimaniKamran Ghoreschi
Jul 4, 2020·Clinical Reviews in Allergy & Immunology·Peter Ip Fung Chun, Heather Lehman
Oct 14, 2020·The Journal of Dermatological Treatment·Kelsey B NusbaumAlan B Fleischer
Dec 5, 2020·Expert Review of Clinical Immunology·Carla Tubau, Lluís Puig
Jun 6, 2020·The Journal of Allergy and Clinical Immunology. in Practice·Takashi NomuraEmma Guttman-Yassky
Mar 24, 2020·The Journal of Investigative Dermatology·Jeffrey D McBride, Mariya Miteva
Oct 19, 2019·The Journal of Investigative Dermatology·Takashi HashimotoGil Yosipovitch
Nov 3, 2020·Drug Discovery Today·Audrey BayletLaurent Delpy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.